Heart attack survival odds have dramatically improved over the past 5 decades, but more people are dying from chronic cardiac ...

Research shows heart attack deaths have plummeted by nearly 90% since 1970, while deaths from heart failure and arrhythmias ...

GLP-1 agonists like Wegovy, Ozempic, and Mounjaro might benefit heart and brain health—but research suggests they might also ...

Researchers at UT Arlington have discovered a key enzyme, IDO1, that when blocked, helps immune cells regain their ability to properly process cholesterol—something that breaks down during ...

Heart attacks are no longer the leading cause of heart disease-related death, but deaths from heart disease have still been responsible for more U.S. fatalities than any other cause, a new American ...

Heart disease is the leading cause of death around the world. However, overall heart disease death rates over the past five ...

With the FDA recently rejecting a drug application that aims to help those living with Barth Syndrome, one Bay Area family is ...

Two specific types of antidepressants – selective serotonin reuptake inhibitors (SSRIs) and tricyclics (TCAs) – may make ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone. Ozempic for blood sugar control and Wegovy for weight loss both use different ...

Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States Food and Drug Administration (FDA) on items ...

Results from a clinical trial of a novel aldosterone synthase inhibitor, lorundrostat, found it significantly reduces ...